AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27189162 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TILs) as a continuous parameter per 10% increase
Number of subjects: 498
Study 27189162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte-predominant breast cancer (LPBC; ≥ 60% TILs)
Number of subjects: 498
Study 27189162 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TILs) in trastuzumab-treated subgroup
Number of subjects: 498
Study 27189162 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TILs) in lapatinib-treated subgroup
Number of subjects: 498
Study 27189162 — intervention group
Group type: EXPERIMENTAL
Intervention: TILs as a prognostic marker for disease-free survival (DFS)
Number of subjects: 498
Study 27189162 — intervention group
Group type: EXPERIMENTAL
Intervention: TILs in triple-positive breast cancer
Number of subjects: 498
Study 25304796 — intervention group
Group type: EXPERIMENTAL
Intervention: RA62.5 (62.5 Gy/25 fractions)
Number of subjects: 21
Study 25304796 — intervention group
Group type: COMPARATOR
Intervention: RA50 (50 Gy/25 fractions)
Number of subjects: 21
Study 22565102 — intervention group
Group type: EXPERIMENTAL
Intervention: CoReg approach
Number of subjects: 20
Study 22565102 — intervention group
Group type: COMPARATOR
Intervention: Usual Care approach
Number of subjects: 20
Study 19696764 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based weight loss intervention with counseling sessions
Number of subjects: 101
Study 19696764 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 101
Study 19696764 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based weight loss intervention among completers
Number of subjects: 101
Study 19696764 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based weight loss intervention with high website utilization
Number of subjects: 101
Study 18728130 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot pack followed by 10‐second stretching
Number of subjects: 29
Study 18728130 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot pack followed by 30‐second stretching
Number of subjects: 29
Study 18728130 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐second stretching
Number of subjects: 29
Study 18728130 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐second stretching
Number of subjects: 29
Study 15664721 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine daily dosing (4, 8, 10, or 12 mg)
Number of subjects: 0
Study 15664721 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine thrice weekly dosing (double maintenance dose on Monday and Wednesday, triple on Friday)
Number of subjects: 0
Study 15664721 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine twice weekly dosing (quadruple maintenance dose on Monday, triple on Friday)
Number of subjects: 0
Study 11912261 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 073 (25 mg)
Number of subjects: 52
Study 11912261 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 073 (50 mg)
Number of subjects: 52
Study 11912261 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 073 (75 mg)
Number of subjects: 52
Study 11912261 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 073 (100 mg)
Number of subjects: 52
Study 11912261 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 073 (25 mg or 50 mg for 8 days)
Number of subjects: 52
Study 11912261 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 073 (50 mg for 8 days)
Number of subjects: 52
Study 11912261 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 073 (any dose)
Number of subjects: 52
Study 11912261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 10090643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (100 g of an amino acid mixture without tryptophan)
Number of subjects: 27
Study 10090643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 g of an amino acid mixture with tryptophan)
Number of subjects: 27
Study 8583092 — intervention group
Group type: EXPERIMENTAL
Intervention: Chili ingestion (5 g chili powder in 100 ml water)
Number of subjects: 16
Study 8583092 — intervention group
Group type: EXPERIMENTAL
Intervention: Chili instillation into the esophagus (same chili suspension)
Number of subjects: 16
Study 8583092 — intervention group
Group type: EXPERIMENTAL
Intervention: Chili ingestion
Number of subjects: 16
Study 2347954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (100 mg)
Number of subjects: 13
Study 2347954 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 13
Study 895007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliquidone
Number of subjects: 0
Study 895007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliflumide
Number of subjects: 0
Study 895007 — intervention group
Group type: COMPARATOR
Intervention: Tolbutamide
Number of subjects: 0
Study 895007 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 0
Study 31375228 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed lingual retainer
Number of subjects: 45
Study 31375228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum‐formed retainer
Number of subjects: 45
Study 31375228 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawley retainer
Number of subjects: 45
Study 28285645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ma-Pi 2 diet
Number of subjects: 12
Study 28285645 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 12
Study 25957043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamically Annotated Visualizations (DAVs)
Number of subjects: 11
Study 25957043 — intervention group
Group type: COMPARATOR
Intervention: Alerts
Number of subjects: 11
Study 23151536 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D(3)/d
Number of subjects: 64
Study 23151536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 21760515 — intervention group
Group type: EXPERIMENTAL
Intervention: Double bending lightwand
Number of subjects: 68
Study 21760515 — intervention group
Group type: COMPARATOR
Intervention: Conventional bending lightwand
Number of subjects: 68
Study 18837970 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy drink enriched with 2.6 g plant sterol esters (1.6 g/d free plant sterol equivalents)
Number of subjects: 50
Study 18837970 — intervention group
Group type: COMPARATOR
Intervention: Soy drink without plant sterols (control)
Number of subjects: 50
Study 17296048 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle Level (explicitly labeled central category)
Number of subjects: 0
Study 17296048 — intervention group
Group type: COMPARATOR
Intervention: Not Sure, Undecided (not explicitly labeled as central)
Number of subjects: 0
Study 14739730 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (100 J)
Number of subjects: 203
Study 14739730 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (150 J)
Number of subjects: 203
Study 14739730 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (200 J)
Number of subjects: 203
Study 14739730 — intervention group
Group type: COMPARATOR
Intervention: Monophasic shock waveform (360 J)
Number of subjects: 203
Study 14739730 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (AF < 48 hours)
Number of subjects: 203
Study 14739730 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (AF > 48 hours)
Number of subjects: 203
Study 14739730 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (AF > 1 year)
Number of subjects: 203
Study 11019933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0
Study 11019933 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 11019933 — intervention group
Group type: COMPARATOR
Intervention: Continuation treatment (general)
Number of subjects: 0
Study 9189212 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid 300 mg daily for 6 months
Number of subjects: 684
Study 9189212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study 9189212 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 684
Study 1415066 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula
Number of subjects: 56
Study 1415066 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 56
Study 1415066 — intervention group
Group type: COMPARATOR
Intervention: Cow milk-based formula
Number of subjects: 56
Study 4013865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine fading
Number of subjects: 130
Study 4013865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine fading/smokeholding
Number of subjects: 130
Study 4013865 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 130
Study 4013865 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 130
Study 31469529 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mW diode laser at 830-nm (TINI group; n=19)
Number of subjects: 38
Study 31469529 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham group; n=19)
Number of subjects: 38
Study 29567006 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging
Number of subjects: 210
Study 29567006 — intervention group
Group type: COMPARATOR
Intervention: Chromoendoscopy
Number of subjects: 210
Study 26822172 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F-Prothrombin Complex Concentrate (4F-PCC)
Number of subjects: 388
Study 26822172 — intervention group
Group type: COMPARATOR
Intervention: Plasma
Number of subjects: 388
Study 24827132 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month trastuzumab treatment
Number of subjects: 261
Study 24827132 — intervention group
Group type: COMPARATOR
Intervention: 6-month trastuzumab treatment
Number of subjects: 261
Study 22488284 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress (73°C) for 30 minutes
Number of subjects: 25
Study 22488284 — intervention group
Group type: COMPARATOR
Intervention: Control (26°C) for 30 minutes
Number of subjects: 25
Study 20939947 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-soaked sheet of regenerated oxidized cellulose positioned in the gallbladder bed
Number of subjects: 45
Study 20939947 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltrated in the muscular fasciae of the trocars' seat
Number of subjects: 45
Study 20939947 — intervention group
Group type: COMPARATOR
Intervention: Control group (no local anesthetic)
Number of subjects: 45
Study 16818527 — intervention group
Group type: EXPERIMENTAL
Intervention: Care for Development Intervention
Number of subjects: 233
Study 16818527 — intervention group
Group type: COMPARATOR
Intervention: Standard health care (comparison group)
Number of subjects: 233
Study 12624612 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg o.d.
Number of subjects: 32
Study 12624612 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg o.d.
Number of subjects: 32
Study 12624612 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg plus Benazepril 10 mg o.d.
Number of subjects: 32
Study 12624612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10960998 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention delivered over 12 weeks
Number of subjects: 38
Study 10960998 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 10960998 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 38
Study 9058296 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 80
Study 9058296 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha + UDCA
Number of subjects: 80
Study 8229544 — intervention group
Group type: EXPERIMENTAL
Intervention: Dioctahedral smectite (DS) 1.5 g freshly dissolved in 50 ml of water, four times daily for 3 days
Number of subjects: 90
Study 8229544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 2944987 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1 ml/kg)
Number of subjects: 0
Study 2944987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31969238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 0.5% podophyllotoxin solution and liquid nitrogen cryotherapy
Number of subjects: 110
Study 31969238 — intervention group
Group type: COMPARATOR
Intervention: Podophyllotoxin
Number of subjects: 110
Study 31969238 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 110
Study 29150922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasella Nose Former (NNF) in Surgical group (15 patients)
Number of subjects: 43
Study 29150922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasella Nose Former (NNF) in Cosmetic group (21 patients)
Number of subjects: 43
Study 29150922 — intervention group
Group type: COMPARATOR
Intervention: Control group in Surgical group (7 patients)
Number of subjects: 43
Study 29150922 — intervention group
Group type: COMPARATOR
Intervention: Control group in Cosmetic group
Number of subjects: 43
Study 27246322 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief thermal sensitization
Number of subjects: 120
Study 27246322 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat pain detection threshold
Number of subjects: 120
Study 27246322 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain during thermal stimulation
Number of subjects: 120
Study 27246322 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Scale
Number of subjects: 120
Study 27246322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 120
Study 25006854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of PRP
Number of subjects: 45
Study 25006854 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical reconstruction of skin scars technique with TCA 100%
Number of subjects: 45
Study 25006854 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined skin needling and PRP
Number of subjects: 45
Study 22456343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet
Number of subjects: 42
Study 22456343 — intervention group
Group type: COMPARATOR
Intervention: Free diet
Number of subjects: 42
Study 20381724 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 0
Study 17507703 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed combination therapy (250 microg beclomethasone and 100 microg albuterol in a single inhaler as needed)
Number of subjects: 455
Study 17507703 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed combination therapy
Number of subjects: 455
Study 17507703 — intervention group
Group type: COMPARATOR
Intervention: Regular beclomethasone therapy (250 microg twice daily)
Number of subjects: 455
Study 17507703 — intervention group
Group type: COMPARATOR
Intervention: Regular combination therapy (250 microg beclomethasone and 100 microg albuterol in a single inhaler twice daily plus 100 microg albuterol as needed)
Number of subjects: 455
Study 17507703 — intervention group
Group type: COMPARATOR
Intervention: As-needed albuterol therapy (100 microg as needed)
Number of subjects: 455
Study 16445830 — intervention group
Group type: EXPERIMENTAL
Intervention: AML 10 trial
Number of subjects: 81
Study 16445830 — intervention group
Group type: EXPERIMENTAL
Intervention: AML 12 trial
Number of subjects: 81
Study 16445830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from AML 10 and AML 12 trials
Number of subjects: 81
Study 16445830 — intervention group
Group type: COMPARATOR
Intervention: ML-DS children vs. non-DS children in trials
Number of subjects: 81
Study 16445830 — intervention group
Group type: EXPERIMENTAL
Intervention: ML-DS children
Number of subjects: 81
Study 12934465 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroid anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 12934465 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs) including cyclosporin A and leflunomid
Number of subjects: 0
Study 12934465 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with 2 or 3 DMARDs
Number of subjects: 0
Study 12934465 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticosteroids (both small daily doses and pulse therapy)
Number of subjects: 0
Study 12934465 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological agents (monoclonal antibodies to TNF alpha and IL-4 or their receptor antagonists)
Number of subjects: 0
Study 12934465 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring methods for treatment safety
Number of subjects: 0
Study 10868713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide via Respimat (RMT) 10 microg per puff, total dose 160 microg
Number of subjects: 36
Study 10868713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide via Respimat (RMT) 20 microg per puff, total dose 320 microg
Number of subjects: 36
Study 10868713 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide via MDI (20 microg per puff, total dose 320 microg)
Number of subjects: 36
Study 10868713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide via RMT (160 microg)
Number of subjects: 36
Study 9541999 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized food mixes
Number of subjects: 0
Study 8225935 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 8225935 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 0
Study 3511692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1232
Study 3511692 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1232
Study 3511692 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1232
Study 30487494 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 118
Study 30487494 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 118
Study 26847379 — intervention group
Group type: EXPERIMENTAL
Intervention: iSTEP (SMS/MMS intervention)
Number of subjects: 21
Study 26847379 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 25034738 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal drainage group
Number of subjects: 219
Study 25034738 — intervention group
Group type: COMPARATOR
Intervention: External drainage group
Number of subjects: 219
Study 22591021 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 0
Study 22591021 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 22591021 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study 20456515 — intervention group
Group type: EXPERIMENTAL
Intervention: bleaching gel + halogen light (group 1)
Number of subjects: 12
Study 20456515 — intervention group
Group type: EXPERIMENTAL
Intervention: bleaching gel (group 2)
Number of subjects: 12
Study 20456515 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control group 3)
Number of subjects: 12
Study 18810400 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0
Study 18810400 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 16183129 — intervention group
Group type: EXPERIMENTAL
Intervention: Microincision cataract surgery (MICS)
Number of subjects: 50
Study 16183129 — intervention group
Group type: COMPARATOR
Intervention: Coaxial phacoemulsification
Number of subjects: 50
Study 12911833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000-2000 micro g/day
Number of subjects: 133
Study 12911833 — intervention group
Group type: COMPARATOR
Intervention: BDP/BUD >/=1750 micro g/day
Number of subjects: 133
Study 12911833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 133
Study 10371231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral smoking cessation program with vigorous exercise
Number of subjects: 281
Study 10371231 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐behavioral smoking cessation program with equal staff contact time (control)
Number of subjects: 281
Study 8800986 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous dipyridamole
Number of subjects: 74
Study 8800986 — intervention group
Group type: COMPARATOR
Intervention: Control group (no significant coronary artery disease)
Number of subjects: 74
Study 1799466 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b alone or in combination with chemotherapy
Number of subjects: 126
Study 1799466 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interferon
Number of subjects: 126
Study 1799466 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon plus low-dose hydroxyurea
Number of subjects: 126
Study 1799466 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alone or combined with chemotherapy
Number of subjects: 126
Study 1799466 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 126
Study 6849533 — intervention group
Group type: EXPERIMENTAL
Intervention: EES (2 injections of epinephrine followed by Sus-Phrine)
Number of subjects: 88
Study 6849533 — intervention group
Group type: EXPERIMENTAL
Intervention: S (Sus-Phrine only)
Number of subjects: 88
Study 6849533 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP (Sus-Phrine followed by 2 placebo injections)
Number of subjects: 88
Study 6849533 — intervention group
Group type: EXPERIMENTAL
Intervention: E (epinephrine only)
Number of subjects: 88
Study 6849533 — intervention group
Group type: COMPARATOR
Intervention: EES, S, SPP (combined)
Number of subjects: 88
Study 29157055 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptotherapy
Number of subjects: 134
Study 29157055 — intervention group
Group type: COMPARATOR
Intervention: Psycho‐education via Internet
Number of subjects: 134
Study 29157055 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 134
Study 28055065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4 g/d)
Number of subjects: 567